

# CLC Clinical Trials Funded

Beginning during the fiscal year 2015-2016 Cancer League of Colorado's Board of Directors approved funding of Investigator Initiated Clinical Trials. As of June 30, 2019 the following Trials have been funded:

<u>Investigator</u>	<u>Project Title</u>	<u>Amount</u>
Karyn A. Goodman, MD, MS	A Dose Escalation Trial of Stereotatic Body Radiotherapy (SBRT) after Induction Chemotherapy for Locally Advanced Pancreatic Cancer	\$ 50,000
Paul Maroni, MD	A Phase 2 Study of Grape Seed Extract (GSE) Product I Asymptomatic Non-Metastatic Prostate Cancer Patients with Rising PSA	\$ 50,000
Clay Smith, MD and Dan Pollyea, MD	Phase I Trial of Arsenic Trioxide with with Cyclophosphamide in Patients with Relapsed/Refractory AML	\$ 50,000
S. Lindsey Davis, MD	Identifying Biomarkers of Immune-Related Toxicity In cancer patients treated with immune checkpoint Inhibitors; a pilot study	\$ 50,000
Elissa Kolva, PhD	Effect of Guided Imagery for Radiotherapy-Related Distress	\$ 50,000
Elizabeth Kessler, MD	Bipolar Testosterone Therapy in Prostate Cancer	\$ 70,000
Jennifer Diamond, MD & Christine Fisher, MD, MPH	A Phase 1b Study of Radiation and Anti-PD-1 Therapy in Recurrent Women's Cancers	\$100,000
Drs. Olsen, Leal and Goodman	Pilot Study of Induction FLOT Followed by Neoadjuvant Chemoradiation in Patients With Resectable Adenocarcinoma of the Esophagus or Gastroesophageal Junction	\$ 50,000
Breelyn A. Wilky, MD	An Open Label, Phase II Efficacy Trial of Doxorubicin and Olaratumab in Combination With Dual Checkpoint Blockade Using agen1884 And agen2034 for Advanced or Metastatic Soft Tissue Sarcomas	\$100,000
Kelly Faulk, MD	Evaluate the Safety and Tolerability and Define the Maximum Tolerated dose (MTD) of Losaratan in	\$ 50,000

Combination with Sunitinib in Pediatric and Young  
Adult Patients with Relapsed or Refractory  
Osteosarcoma

Rao Mushtaq, MD; Ross  
Camidge, PhD; Rustain  
Morgan, MD; Micol  
Rothman, MD

Study Relating to Exploring the Potential Differential  
Need for Anti-resorptive Bone Medications  
(Bisphosphonates or RANK-L Inhibitors) in Patients  
with Advanced Non-Small Cell Lung Cancer and Bone  
Metastases With and Without Actionable Driver  
Mutations

\$ 50,000